Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Nature. 2020 Jul 15;584(7821):443–449. doi: 10.1038/s41586-020-2548-6

Extended Data Figure 4. Serum or plasma mAbs competition binding.

Extended Data Figure 4.

a. Inhibition of hACE2 binding to S2Pecto by serum or plasma of four SARS-CoV-2 immune subjects or one non-immune control in ELISA using SARS-CoV-2 S2Pecto. mAbs were isolated from subjects 3 and 4 as described previously5. Mean ± SD of triplicates of one experiment is shown. Dotted line indicates full inhibition (100%) of hACE2 by 500 ng/mL of control mAb COV2-2196 or COV2-2130.

b. Inhibition of mAb COV2-2130 (left) or COV2-2196 (right) binding to S2Pecto by serum or plasma of four SARS-CoV-2 immune subjects or one non-immune control in ELISA using SARS-CoV-2 S2Pecto. Mean ± SD of triplicates and representative of two experiments are shown. Dotted line indicates percent of self-competition of mAb COV2-2196 and-2130 on the SARS-CoV-2 S2Pecto antigen.